Annual Total Liabilities
$80.04 M
+$50.53 M+171.24%
December 31, 2024
Summary
- As of March 13, 2025, DAWN annual total liabilities is $80.04 million, with the most recent change of +$50.53 million (+171.24%) on December 31, 2024.
- During the last 3 years, DAWN annual total liabilities has risen by +$71.36 million (+822.83%).
- DAWN annual total liabilities is now -15.00% below its all-time high of $94.16 million, reached on December 31, 2020.
Performance
DAWN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$80.04 M
+$34.69 M+76.51%
December 31, 2024
Summary
- As of March 13, 2025, DAWN quarterly total liabilities is $80.04 million, with the most recent change of +$34.69 million (+76.51%) on December 31, 2024.
- Over the past year, DAWN quarterly total liabilities has increased by +$34.69 million (+76.51%).
- DAWN quarterly total liabilities is now -64.42% below its all-time high of $224.95 million, reached on March 31, 2021.
Performance
DAWN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
DAWN Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +171.2% | +76.5% |
| 3 y3 years | +822.8% | +76.5% |
| 5 y5 years | +146.1% | +76.5% |
DAWN Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +822.8% | -14.6% | +878.9% |
| 5 y | 5-year | -15.0% | +822.8% | -64.4% | +1576.5% |
| alltime | all time | -15.0% | +822.8% | -64.4% | +1576.5% |
Day One Biopharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $80.04 M(+171.2%) | $80.04 M(+76.5%) |
| Sep 2024 | - | $45.34 M(-51.6%) |
| Jun 2024 | - | $93.71 M(+214.0%) |
| Mar 2024 | - | $29.84 M(+1.1%) |
| Dec 2023 | $29.51 M(+73.3%) | $29.51 M(+20.2%) |
| Sep 2023 | - | $24.55 M(-0.6%) |
| Jun 2023 | - | $24.70 M(+6.7%) |
| Mar 2023 | - | $23.15 M(+36.0%) |
| Dec 2022 | $17.02 M | $17.02 M(-9.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $18.79 M(+40.0%) |
| Jun 2022 | - | $13.42 M(+64.1%) |
| Mar 2022 | - | $8.18 M(-5.7%) |
| Dec 2021 | $8.67 M(-90.8%) | $8.67 M(+41.9%) |
| Sep 2021 | - | $6.11 M(+28.0%) |
| Jun 2021 | - | $4.77 M(-97.9%) |
| Mar 2021 | - | $224.95 M(+138.9%) |
| Dec 2020 | $94.16 M(+189.5%) | $94.16 M |
| Dec 2019 | $32.52 M | - |
FAQ
- What is Day One Biopharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Day One Biopharmaceuticals?
- What is Day One Biopharmaceuticals annual total liabilities year-on-year change?
- What is Day One Biopharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Day One Biopharmaceuticals?
- What is Day One Biopharmaceuticals quarterly total liabilities year-on-year change?
What is Day One Biopharmaceuticals annual total liabilities?
The current annual total liabilities of DAWN is $80.04 M
What is the all time high annual total liabilities for Day One Biopharmaceuticals?
Day One Biopharmaceuticals all-time high annual total liabilities is $94.16 M
What is Day One Biopharmaceuticals annual total liabilities year-on-year change?
Over the past year, DAWN annual total liabilities has changed by +$50.53 M (+171.24%)
What is Day One Biopharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of DAWN is $80.04 M
What is the all time high quarterly total liabilities for Day One Biopharmaceuticals?
Day One Biopharmaceuticals all-time high quarterly total liabilities is $224.95 M
What is Day One Biopharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, DAWN quarterly total liabilities has changed by +$34.69 M (+76.51%)